ライフサイエンスコーパス: accessory pathway

1 ial ablation fails in the elimination of the accessory pathway.

2 seemed to be driven by a right anteroseptal accessory pathway.

3 ciprocating tachycardia (ORT) using a septal accessory pathway.

4 shing atypical AVNRT from ORT using a septal accessory pathway.

5 ay in the concealed, retrogradely conducting accessory pathway.

6 e to slowing of retrograde conduction in the accessory pathway.

7 agnostic of the presence of a left free wall accessory pathway.

8 squerading as tachycardia using a left-sided accessory pathway.

9 on, masquerading as tachycardia using a left accessory pathway.

10 patients undergoing catheter ablation of an accessory pathway.

11 ochrome P450 2B6 (CYP2B6), with CYP2A6 as an accessory pathway.

12 de conduction, suggesting the presence of an accessory pathway.

13 to an age-matched cohort with nondecremental accessory pathways.

14 erwent ablation for epicardial posteroseptal accessory pathways.

15 lopment of the cardiac conduction system and accessory pathways.

16 in 13 patients, including 4 with left-sided accessory pathways.

17 patients, 9%); 6) epicardial location of the accessory pathway (5 patients, 8%); 7) recurrent atrial

18 apping error due to an oblique course of the accessory pathway (7 patients, 11%); 4) failure to recog

19 tes (87.6% versus 90.6%, P=0.11), for single accessory pathways (94.5% versus 91.5%, P=0.4), or for t

20 tiate atypical AVNRT from ORT using a septal accessory pathway, a definitive diagnosis is occasionall

21 ), and the percentage of patients undergoing accessory pathway ablation was greatest in the <60-year-

22 period of 7 years, 2 patients had undergone accessory pathway ablation, 8 patients (36%) underwent p

23 males) referred for percutaneous epicardial accessory pathway ablation.

24 ocedure may facilitate successful outcome of accessory pathway ablation.

25 ventricular pre-excitation or had undergone accessory pathway ablation; 17 (19%) had pacemakers (med

26 y be beneficial, along with consideration of accessory-pathway ablation in those deemed to be at high

27 ith ablations for (1) anterior and midseptal accessory pathways and atrioventricular nodal reentry an

28 ocardium of mice can produce fully penetrant accessory pathways and ventricular preexcitation.

29 -12 secretion is dependent on the CD40L/CD40 accessory pathway, and, utilizing a Th cell-free system,

30 ventricular preexcitation involving multiple accessory pathways, and conduction system disease, inclu

31 ndings highlighting the role of key enzymes, accessory pathways, and posttranslational protein modifi

32 f the atrial or ventricular insertion of the accessory pathway; and 7) searching within the coronary

33 , 11 years), and was associated with a short accessory pathway antegrade refractory period (P<0.001)

34 o identify risk factors for recurrence after accessory pathway (AP) ablation.

35 The role of adenosine in uncovering dormant accessory pathway (AP) conduction after AP ablation is u

36 adequacy of electrophysiological mapping of accessory pathway (AP) locations in 15 patients at 27 ta

37 CSAP was defined by accessory pathway (AP) potential or earliest activation

38 Adverse accessory pathway (AP) properties were defined according

39 patients had a right- and 4 had a left-sided accessory pathway (AP), 4 patients had inappropriate sin

40 ular nodal reentrant tachycardia (AVNRT), an accessory pathway (AP), or the atrioventricular junction

41 Transcatheter ablation of accessory pathway (AP)-mediated tachycardia is routinely

42 nosis between tachycardia mediated by septal accessory pathways (AP) and atypical atrioventricular no

43 Nodoventricular and nodofascicular accessory pathways (AP) are uncommon connections between

44 e and the characteristics of the responsible accessory pathways (AP).

45 de on the conduction system in patients with accessory pathways (AP).

46 Accessory pathways are a common cause of supraventricula

47 1%); 4) failure to recognize a posteroseptal accessory pathway as being left-sided instead of right-s

48 Radiofrequency ablation of accessory pathways at times requires a lengthy procedure

49 on alone eliminated epicardial posteroseptal accessory pathway conduction in 17 of 26 (65%) patients

50 For AVRT, a sustained effect on accessory pathway conduction occurred -3.3 +/- 4.9 s aft

51 d that some posteroseptal and left posterior accessory pathways (CSAPs) result from connections betwe

52 terograde effective refractory period of the accessory pathway cutoff of 240 milliseconds.

53 T) in patients with decrementally conducting accessory pathway (DAP) is a helpful maneuver to prove p

54 Although retrograde decremental accessory pathways (DAPs) are thought to typically prese

55 omatic and asymptomatic children had similar accessory pathway effective refractory periods and supra

56 ltivariable analysis demonstrated that short accessory-pathway effective refractory period (P<0.001)

57 up with malignant arrhythmias showed shorter accessory-pathway effective refractory period (P<0.001)

58 These results suggest that GC inhibit accessory pathways for IL-2 production via CD28 by predo

59 syndrome to help elucidate the mechanisms of accessory pathway formation.

60 for NIK as a histone H3 modifier, through an accessory pathway from NIK to IKKalpha, that could play

61 e of the 44 patients with ORT using a septal accessory pathway had an S-A-VA interval >85 ms and PPI-

62 rd of heart failure for a right anteroseptal accessory pathway (HR, 5.88; 95% CI, 2.63-13.1).

63 xtrastimuli showed evidence of a decremental accessory pathway in 3 of the 4 cases.

64 The accessory pathway in the 65 patients in this study was l

65 y in 4 and, after successful ablation of the accessory pathway, in 7.

66 For patients with midseptal and parahissian accessory pathways, in whom the risk of producing inadve

67 ntricular dissociation ruling out extranodal accessory pathways, including atriofascicular pathways.

68 procainamide-sensitive, adenosine-resistant accessory pathways induced in postnatal life that may ra

69 t AF patients and 27 patients with left-side accessory pathway (LAP) underwent left atrial mapping du

70 t-sided (4 patients, 6%); 5) other errors in accessory pathway localization (6 patients, 9%); 6) epic

71 spect of catheter manipulation and errors in accessory pathway localization.

72 Subgroup analysis on accessory pathway location revealed a higher adjusted ha

73 of multiple pathways (20% vs 16% vs 16%) or accessory pathway location.

74 or failed attempt at catheter ablation of an accessory pathway may be due to a variety of reasons, th

75 reentry tachycardia (n = 13), reentry via an accessory pathway (n = 4) or via twin atrioventricular n

76 Neither success for infants with a single accessory pathway nor complications for the entire infan

77 tory Ca(2+) is not bound, which generates an accessory pathway of activation; and 5), there is incomp

78 ant tachycardia (AVNRT) and atrioventricular accessory pathways or atrioventricular reciprocating tac

79 ]/with [n=3] a bystander nodofascicular [NF] accessory pathway, orthodromic reciprocating tachycardia

80 (P<0.001) and more often exhibited multiple accessory pathways (P<0.001), and atrioventricular reent

81 [50%]), or terminated (5/8 [63%]) SVT in all accessory pathway patients.

82 ing within the coronary sinus for a presumed accessory pathway potential.

83 ay proliferative responses, whereas CD2/CD28 accessory pathway proliferative responses are relatively

84 Ablation of the accessory pathway provides definitive treatment for PJRT

85 have been reported with atrial tachycardias, accessory pathway reciprocating tachycardias, atrioventr

86 underlying the development and conduction of accessory pathways remain unknown.

87 Ablation of epicardial posteroseptal accessory pathways requires ablation within the coronary

88 drome, this enabled understanding of complex accessory pathways resistant to previous ablation.

89 stimulatory signals through the LFA-1/ICAM-1 accessory pathway that are sufficient to induce early Th

90 t manifestation in 80% of the children of an accessory pathway that can precipitate a life-threatenin

91 ion (2 patients, 3%); 9) unusual right-sided accessory pathway that inserted in the anterior right ve

92 White syndrome, is caused by the presence of accessory pathways that can rapidly conduct electrical i

93 r homeostatic response and also the indirect accessory pathways that deal with copper-induced damage.

94 patients undergoing catheter ablation of an accessory pathway, the mean ablation time +/- SD was 68

95 VNRT and 44 patients with ORT using a septal accessory pathway, the right ventricle was paced at a cy

96 Epicardial mapping and ablation of accessory pathways through a subxiphoid approach can be

97 ogramming, to allow robust conduction across accessory pathway tissue.

98 vely localize ventricular insertion sites of accessory pathways to guide ablation and evaluate its ou

99 nothrombosis, platelet aggregation and other accessory pathways to platelet activation and clot forma

100 n=4] or NF [NF reentrant tachycardia; n=2]) accessory pathway underwent electrophysiological study.

101 A distinct AV accessory pathway was confirmed by electrical and pharma

102 Ablation of the accessory pathway was successful in 19 of 21 patients.

103 Bystander accessory pathways were only identified by His-refractor

104 tched control population with nondecremental accessory pathways who underwent electrophysiology study